If the FDA clears the cancer drug Tykerb this week, it could be seen as support for a new research-and-development technique used by GlaxoSmithKline. The breast-cancer drug was sent to the FDA for review under a new company policy granting scientists in seven specific disease areas more autonomy over research conducted in their areas.

Related Summaries